Literature DB >> 10147253

The economics of treating obesity.

J Hutton1.   

Abstract

Obesity has become a major contemporary public health concern. The excess burden of disease associated with obesity (e.g. cardiovascular disease, diabetes mellitus, gallbladder disease) results in considerable costs to society, while the indirect costs of obesity include decreased labour input and lower educational achievement. Obese individuals have decreased quality of life and life expectancy. Furthermore, society's stigmatisation of the obese results in decreased opportunities in education, housing and employment. Obesity may be treated by behavioural modification (dieting, exercise), or by interventionist means (pharmacotherapy, jaw-wiring, surgery). The method of weight reduction should be chosen to suit the individual patient; interventionist approaches may be required for patients with severe obesity. Studies to examine the cost and quality of life implications of the various treatment modalities are needed.

Entities:  

Mesh:

Year:  1994        PMID: 10147253     DOI: 10.2165/00019053-199400051-00014

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  15 in total

1.  Cost-of-illness studies: a major headache?

Authors:  M Drummond
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

2.  The cost of obesity: the US perspective.

Authors:  A M Wolf; G A Colditz
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

3.  Towards a new approach for estimating indirect costs of disease.

Authors:  M A Koopmanschap; B M van Ineveld
Journal:  Soc Sci Med       Date:  1992-05       Impact factor: 4.634

Review 4.  Socioeconomic consequences of obesity: the effect of obesity on the individual.

Authors:  G Enzi
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

5.  Obesity in Europe: prevalence and consequences for use of medical care.

Authors:  J C Seidell; I Deerenberg
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

6.  The cost of obesity: the Australian perspective.

Authors:  L Segal; R Carter; P Zimmet
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

7.  Health-related quality of life assessment and the pharmaceutical industry.

Authors:  D A Revicki; M Rothman; B Luce
Journal:  Pharmacoeconomics       Date:  1992-06       Impact factor: 4.981

8.  Economics of coronary artery bypass grafting.

Authors:  A Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-03

9.  Morbid obesity and related health risks.

Authors:  J G Kral
Journal:  Ann Intern Med       Date:  1985-12       Impact factor: 25.391

Review 10.  Beneficial health effects of modest weight loss.

Authors:  D J Goldstein
Journal:  Int J Obes Relat Metab Disord       Date:  1992-06
View more
  3 in total

Review 1.  Effective management of obesity.

Authors:  S O'Meara; A M Glenny; C Wilson; A Melville; T A Sheldon
Journal:  Qual Health Care       Date:  1997-09

Review 2.  Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.

Authors:  R Davis; D Faulds
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

Review 3.  Sibutramine. A review of its contribution to the management of obesity.

Authors:  W McNeely; K L Goa
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.